These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34554982)

  • 1. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
    Maulden A
    Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 5. Can we learn lessons from the FDA's approval of aducanumab?
    Liu KY; Howard R
    Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.
    Dunn B; Stein P; Cavazzoni P
    JAMA Intern Med; 2021 Oct; 181(10):1276-1278. PubMed ID: 34254984
    [No Abstract]   [Full Text] [Related]  

  • 8. Aducanumab (Aduhelm) for Alzheimer's disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258
    [No Abstract]   [Full Text] [Related]  

  • 9. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 10. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
    Fleck LM
    Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated Approval of Aducanumab: Where Do We Stand Now?
    Barenholtz Levy H
    Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.
    Herder M
    J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making the Case for Accelerated Withdrawal of Aducanumab.
    Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
    J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 15. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 16. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 17. A carte blanche approval in Alzheimer's.
    Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
    [No Abstract]   [Full Text] [Related]  

  • 18. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
    Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
    Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making the Case for the Accelerated Withdrawal of Aducanumab.
    Whitehouse PJ; Saini V
    J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.